A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

NCT07202884 · Recruiting

Last updated 2026-05-28

This study is testing the medication orforglipron in women with stress urinary incontinence who also have obesity or overweight to see how it affects the number of leakage episodes.

Status Recruiting Currently enrolling participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 1,000 people Planned (estimated).

Who can join Ages 18+ · female only

Timeline Started 2025-09 · est. completion 2028-03

Where 137 sites · Canada, China, Czechia, India, Japan, Mexico, Poland, Romania, South Korea, United States

What this study is testing ClinicalTrials.gov NCT07202884 ↗

Description as written by the study sponsor.

The GZPS master protocol will support two independent studies, J2A-MC-GZS1 and J2A-MC-GZS2. Each study will see how well and safely orforglipron works in adult female participants with stress urinary incontinence (SUI) who have obesity or overweight. SUI is leaking urine during movement or activity such as coughing or exercising. Participation in the study will last about 58 weeks from screening to safety follow-up.

Treatments tested

Orforglipron also known as LY3502970 Drug

Administered orally
Placebo Drug

Administered orally

Main thing measured	Change from Baseline in Incontinence Episode Frequency (IEF)
Sponsor	Eli Lilly and Company
Conditions studied	Urinary Incontinence,Stress
GLP-1 drugs	orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07202884 ↗